AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16326121 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone combination (50/250 mcg by Diskus) for 1 week
Number of subjects: 9
Study 12415061 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (at least 0.016 mg/kg/IgE [IU/mL] per 4 weeks)
Number of subjects: 0
Study 12415061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10613625 — intervention group
Group type: COMPARATOR
Intervention: Cholesteryl ester and phospholipid fractions
Number of subjects: 1100
Study 10613625 — intervention group
Group type: COMPARATOR
Intervention: Red cell fraction
Number of subjects: 1100
Study 10613625 — intervention group
Group type: COMPARATOR
Intervention: Triglyceride fraction
Number of subjects: 1100
Study 10613625 — intervention group
Group type: COMPARATOR
Intervention: Phospholipid and red cell fractions
Number of subjects: 1100
Study 7497558 — intervention group
Group type: EXPERIMENTAL
Intervention: nicardipine 30 micrograms.kg‐1 iv (Group N, n = 12)
Number of subjects: 37
Study 7497558 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem 0.3 mg.kg‐1 (Group D, n = 12)
Number of subjects: 37
Study 7497558 — intervention group
Group type: COMPARATOR
Intervention: saline placebo (Group C, n = 13)
Number of subjects: 37
Study 2023098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 600 mg daily for 28 days
Number of subjects: 18
Study 2023098 — intervention group
Group type: COMPARATOR
Intervention: Control (nontreated patients)
Number of subjects: 18
Study 7259970 — intervention group
Group type: EXPERIMENTAL
Intervention: Facemask
Number of subjects: 15
Study 7259970 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthpiece
Number of subjects: 15
Study 31046826 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogic Book-sharing (DBS)
Number of subjects: 369
Study 31046826 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT Raising Safe Kids Program (ACT)
Number of subjects: 369
Study 31046826 — intervention group
Group type: COMPARATOR
Intervention: Control group (neither intervention)
Number of subjects: 369
Study 29073947 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 months of dual antiplatelet therapy (DAPT)
Number of subjects: 25416
Study 29073947 — intervention group
Group type: COMPARATOR
Intervention: 12 months of dual antiplatelet therapy (DAPT)
Number of subjects: 25416
Study 26618848 — intervention group
Group type: EXPERIMENTAL
Intervention: $40 minigrant in the form of a voucher, valid at a local gardening store
Number of subjects: 60
Study 26618848 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 23982170 — intervention group
Group type: EXPERIMENTAL
Intervention: CareLink(®) with diabetes-team initiated contact
Number of subjects: 70
Study 23982170 — intervention group
Group type: EXPERIMENTAL
Intervention: CareLink(®) without diabetes-team initiated contact
Number of subjects: 70
Study 23982170 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 70
Study 21956772 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0
Study 21956772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19640331 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d for 4 weeks)
Number of subjects: 86
Study 19640331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 17244765 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (STS) 6 mg/24 h
Number of subjects: 0
Study 17244765 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam, Olanzapine, Risperidone (test drugs)
Number of subjects: 0
Study 14699269 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolotherapy injections (20% glucose/0.2% lignocaine)
Number of subjects: 110
Study 14699269 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injections
Number of subjects: 110
Study 14699269 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion/extension exercises
Number of subjects: 110
Study 14699269 — intervention group
Group type: COMPARATOR
Intervention: Normal activity
Number of subjects: 110
Study 12131888 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite (Z100)
Number of subjects: 10
Study 12131888 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional glass ionomer cement (Fuji IX)
Number of subjects: 10
Study 12131888 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement (Fuji II LC)
Number of subjects: 10
Study 12131888 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel
Number of subjects: 10
Study 10372729 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Reduction (WR) with a very low calorie diet for 8-12 weeks
Number of subjects: 20
Study 10372729 — intervention group
Group type: COMPARATOR
Intervention: Combined Oral Contraceptives (OC) treatment for 12 weeks
Number of subjects: 20
Study 7502546 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (11 g/day)
Number of subjects: 12
Study 7502546 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (CO) supplementation (11 g/day)
Number of subjects: 12
Study 2248531 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin (25 mg/kg/day) plus cimetidine for six weeks
Number of subjects: 23
Study 2248531 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine alone
Number of subjects: 23
Study 395255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal live allantoic influenza vaccine
Number of subjects: 0
Study 395255 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral live allantoic influenza vaccine
Number of subjects: 0
Study 395255 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 31511012 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiochemotherapy in sarcopenic patients
Number of subjects: 61
Study 31511012 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant radiochemotherapy in non-sarcopenic patients
Number of subjects: 61
Study 31511012 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications in sarcopenic patients
Number of subjects: 61
Study 31511012 — intervention group
Group type: COMPARATOR
Intervention: Postoperative complications in non-sarcopenic patients
Number of subjects: 61
Study 31511012 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival in sarcopenic patients
Number of subjects: 61
Study 31511012 — intervention group
Group type: COMPARATOR
Intervention: Survival in non-sarcopenic patients
Number of subjects: 61
Study 29393837 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 80
Study 29393837 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 80
Study 29393837 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived burdensomeness
Number of subjects: 80
Study 29393837 — intervention group
Group type: EXPERIMENTAL
Intervention: Thwarted belongingness
Number of subjects: 80
Study 26403017 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 atm abs breathing 100% oxygen
Number of subjects: 50
Study 26403017 — intervention group
Group type: COMPARATOR
Intervention: Sham (1.3 atm-abs air)
Number of subjects: 50
Study 23255270 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 20 ml of normal saline into the knee joint cavity
Number of subjects: 44
Study 23255270 — intervention group
Group type: COMPARATOR
Intervention: Control group (no joint infusion)
Number of subjects: 44
Study 21362327 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 93
Study 21362327 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (D)
Number of subjects: 93
Study 21362327 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus Exercise (DEX)
Number of subjects: 93
Study 21362327 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 93
Study 19258409 — intervention group
Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 141
Study 19258409 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-endurance training
Number of subjects: 141
Study 19258409 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-resistance training
Number of subjects: 141
Study 17597333 — intervention group
Group type: EXPERIMENTAL
Intervention: Short pulse width (60-90 micros)
Number of subjects: 20
Study 17597333 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium pulse width (120-150 micros)
Number of subjects: 20
Study 17597333 — intervention group
Group type: EXPERIMENTAL
Intervention: Long pulse width (450 micros)
Number of subjects: 20
Study 14693169 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplant
Number of subjects: 2
Study 14693169 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic anticoagulation
Number of subjects: 2
Study 11069509 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% dilution of fluticasone propionate (FP) 0.05% cream for 2 weeks
Number of subjects: 31
Study 11069509 — intervention group
Group type: EXPERIMENTAL
Intervention: 5%, 10%, and 25% dilutions of FP cream under wet wrap
Number of subjects: 31
Study 11069509 — intervention group
Group type: EXPERIMENTAL
Intervention: 0%, 5%, 10%, and 25% dilutions of FP cream applied on the whole body under wet wrap
Number of subjects: 31
Study 11069509 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements of 09.00 h serum cortisol after 2 weeks
Number of subjects: 31
Study 11069509 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements of 06.00 h serum cortisol levels
Number of subjects: 31
Study 8850903 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-reducing mattresses
Number of subjects: 0
Study 1476055 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 80
Study 1476055 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy
Number of subjects: 80
Study 1476055 — intervention group
Group type: COMPARATOR
Intervention: Various additional therapies
Number of subjects: 80
Study 6425893 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospholipid liposomes (PL) 250 mg IV bolus plus additional 250 mg infused IV over 60 minutes
Number of subjects: 8
Study 6425893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3722852 — intervention group
Group type: EXPERIMENTAL
Intervention: RTU + instillation of Thiotepa
Number of subjects: 135
Study 3722852 — intervention group
Group type: EXPERIMENTAL
Intervention: RTU followed by instillations of Adriamycin
Number of subjects: 135
Study 3722852 — intervention group
Group type: COMPARATOR
Intervention: RTU alone
Number of subjects: 135
Study 29843492 — intervention group
Group type: COMPARATOR
Intervention: 75 mg daily clopidogrel
Number of subjects: 376
Study 29843492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 376
Study 29843492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 376
Study 29843492 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg daily clopidogrel or triple therapy with clopidogrel and cilostazol
Number of subjects: 376
Study 27388980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative remifentanil (0.4 μg × kg−1 × min−1)
Number of subjects: 23
Study 27388980 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative sufentanil (0.25 μg × kg−1 bolus, 0.15 μg × kg−1, repetition after 60 min)
Number of subjects: 23
Study 24711073 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg PHGG daily for 4 weeks
Number of subjects: 49
Study 23583011 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (40-160 mg/day)
Number of subjects: 0
Study 23583011 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine XR (200-800 mg/day)
Number of subjects: 0
Study 23583011 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 0
Study 23583011 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine XR
Number of subjects: 0
Study 20826963 — intervention group
Group type: EXPERIMENTAL
Intervention: High thoracic epidural analgesia (HTEA)
Number of subjects: 62
Study 18696370 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing plus brief office intervention
Number of subjects: 196
Study 18696370 — intervention group
Group type: COMPARATOR
Intervention: Brief office intervention
Number of subjects: 196
Study 16873779 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet
Number of subjects: 99
Study 16873779 — intervention group
Group type: COMPARATOR
Intervention: ADA diet
Number of subjects: 99
Study 15057387 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% sucrose solution
Number of subjects: 11
Study 15057387 — intervention group
Group type: COMPARATOR
Intervention: Distilled deionized water
Number of subjects: 11
Study 10954063 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 53
Study 10954063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 8777332 — intervention group
Group type: COMPARATOR
Intervention: 8.2 kb Bam‐HI ALR2 genotype
Number of subjects: 128
Study 8777332 — intervention group
Group type: COMPARATOR
Intervention: 8.2 kb allele
Number of subjects: 128
Study 8777332 — intervention group
Group type: COMPARATOR
Intervention: 10/9.2-8.2 kb TCRBC-ALR2 genotype
Number of subjects: 128
Study 8777332 — intervention group
Group type: COMPARATOR
Intervention: 10/9.2 and 9.2/9.2 kb TCRBC-ALR2 haplotypes
Number of subjects: 128
Study 1599073 — intervention group
Group type: EXPERIMENTAL
Intervention: Music played through headphones from 5 min before induction of anaesthesia to 15 min postoperatively
Number of subjects: 50
Study 1599073 — intervention group
Group type: COMPARATOR
Intervention: No music (control group)
Number of subjects: 50
Study 6209194 — intervention group
Group type: EXPERIMENTAL
Intervention: Azatadine 2 X 1 mg daily
Number of subjects: 0
Study 6209194 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine 2 X 60 mg daily
Number of subjects: 0
Study 31492796 — intervention group
Group type: EXPERIMENTAL
Intervention: Online anticoagulation management model
Number of subjects: 496
Study 31492796 — intervention group
Group type: COMPARATOR
Intervention: Offline anticoagulation management model
Number of subjects: 496
Study 30485224 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative lumbar drainage (LD)
Number of subjects: 170
Study 30485224 — intervention group
Group type: COMPARATOR
Intervention: No lumbar drainage (control group)
Number of subjects: 170
Study 30485224 — intervention group
Group type: EXPERIMENTAL
Intervention: Defect size measured intraoperatively
Number of subjects: 170
Study 27974012 — intervention group
Group type: EXPERIMENTAL
Intervention: SWC+US (standard wound care + ultrasound)
Number of subjects: 77
Study 27974012 — intervention group
Group type: EXPERIMENTAL
Intervention: SWC+ES (standard wound care + electrical stimulation)
Number of subjects: 77
Study 27974012 — intervention group
Group type: COMPARATOR
Intervention: SWC (standard wound care)
Number of subjects: 77
Study 24604439 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Telemedical Support (CTS)
Number of subjects: 34
Study 24604439 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study 23008288 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimarker reverse‐transcriptase quantitative polymerase chain reaction (RT‐qPCR) detection of circulating tumor cells (CTCs)
Number of subjects: 331
Study 23008288 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 331
Study 23008288 — intervention group
Group type: COMPARATOR
Intervention: BCG placebo
Number of subjects: 331
Study 19930174 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0
Study 19930174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17990455 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Yanghe Decoction (YHD) combined with prednisone
Number of subjects: 61
Study 17990455 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone (Control)
Number of subjects: 61
Study 15605280 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body bioelectrical impedance analysis
Number of subjects: 200
Study 15605280 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal bioelectrical impedance analysis
Number of subjects: 200
Study 15605280 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal bioelectrical impedance analysis
Number of subjects: 200
Study 12390596 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline monohydrate 100 mg daily tablet
Number of subjects: 522
Study 12390596 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine-proguanil (C/P) capsule
Number of subjects: 522
Study 11052580 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored FEC regimen with G-CSF support (n=251)
Number of subjects: 525
Study 11052580 — intervention group
Group type: COMPARATOR
Intervention: CTCb group (n=274)
Number of subjects: 525
Study 11052580 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored FEC group (n=251)
Number of subjects: 525
Study 8803666 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate (specific dosing strategies not detailed)
Number of subjects: 0
Study 1739192 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic albuterol MDI (2 puffs, 180 micrograms)
Number of subjects: 17
Study 1739192 — intervention group
Group type: COMPARATOR
Intervention: Ventolin MDI (2 puffs, 180 micrograms)
Number of subjects: 17
Study 1739192 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic albuterol MDI (primed, 2 puffs)
Number of subjects: 17
Study 1739192 — intervention group
Group type: COMPARATOR
Intervention: Ventolin MDI (primed, 2 puffs)
Number of subjects: 17
Study 6695835 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain triglycerides (LCT)
Number of subjects: 6
Study 6695835 — intervention group
Group type: COMPARATOR
Intervention: Medium-chain triglycerides (MCT)
Number of subjects: 6
Study 30216622 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT)
Number of subjects: 857
Study 30216622 — intervention group
Group type: COMPARATOR
Intervention: Control group (not on TRT, Group 2a)
Number of subjects: 857
Study 29181804 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity aerobic interval exercise (twice-weekly pre-operative supervised sessions)
Number of subjects: 60
Study 29181804 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only (control group)
Number of subjects: 60
Study 27058301 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens 0.625 mg/bazedoxifene 20 mg
Number of subjects: 1583
Study 27058301 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens 0.45 mg/bazedoxifene 20 mg
Number of subjects: 1583
Study 27058301 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens/medroxyprogesterone acetate
Number of subjects: 1583
Study 27058301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1583
Study 27058301 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens/bazedoxifene
Number of subjects: 1583
Study 24885828 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care intervention for frail elderly
Number of subjects: 0
Study 24885828 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21292793 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide as a slow intravenous infusion over 15 min plus placebo (SIG)
Number of subjects: 140
Study 21292793 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide as an intravenous bolus infusion over 2 min plus placebo (BIG)
Number of subjects: 140
Study 20528232 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncovex(GM‐CSF)
Number of subjects: 0
Study 20528232 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 18662969 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CVP
Number of subjects: 321
Study 18662969 — intervention group
Group type: COMPARATOR
Intervention: CVP
Number of subjects: 321
Study 16288158 — intervention group
Group type: EXPERIMENTAL
Intervention: Folk play program (40 min, 5 times a week for 4 weeks)
Number of subjects: 33
Study 16288158 — intervention group
Group type: COMPARATOR
Intervention: Control group (gymnastics and walking program)
Number of subjects: 33
Study 12807615 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based interactive video training (CS)
Number of subjects: 0
Study 12807615 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture site training (LS)
Number of subjects: 0
Study 12807615 — intervention group
Group type: COMPARATOR
Intervention: Control site (CON)
Number of subjects: 0
Study 12938523 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (perioperative application)
Number of subjects: 38
Study 12938523 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug given)
Number of subjects: 38
Study 8697059 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol injections, 3 times a week for 4 weeks, with diet and walking
Number of subjects: 70
Study 8697059 — intervention group
Group type: EXPERIMENTAL
Intervention: Ointment containing forskolin, yohimbine, and aminophylline, applied 5 times a week for 4 weeks after hypertonic warm soaks, with diet and walking
Number of subjects: 70
Study 8697059 — intervention group
Group type: COMPARATOR
Intervention: Forskolin ointment, applied 5 times a week for 4 weeks, with diet and walking
Number of subjects: 70
Study 8697059 — intervention group
Group type: COMPARATOR
Intervention: Yohimbine ointment, applied 5 times a week for 4 weeks, with diet and walking
Number of subjects: 70
Study 8697059 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline ointment, 10%, applied 5 times a week for 6 weeks, with diet and walking
Number of subjects: 70
Study 8697059 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline cream, 2%, applied without diet or walking
Number of subjects: 70
Study 8697059 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline cream, 0.5%, applied without diet or walking
Number of subjects: 70
Study 2334303 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of physostigmine under double-blind placebo-controlled conditions
Number of subjects: 0
Study 2334303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 573185 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy milk
Number of subjects: 48
Study 573185 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 48